SmytheMAKoerberJMForsythLLPriziolaJLBalasubramaniamMMattsonJC.Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy. 2009;29:1073-1081. doi:10.1592/phco.29.9.1073
2.
GilmoreJFAdamsCDBlumRMFanikosJAnne HirningBMattaL.Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. Am J Hematol. 2015;90:E143-E145. doi:10.1002/ajh.24042
3.
AljabriAHuckleberryYKarnesJH, et al. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood. 2016;128:3043-3051. doi:10.1182/blood-2016-07-728030
4.
DoepkerBMountKLRyderLJGerlachATMurphyCVPhilipsGS.Bleeding risk factors associated with argatroban therapy in the critically ill. J Thromb Thrombolysis. 2012;34:491-498. doi:10.1007/s11239-012-0758-y
